Alveolar cell apoptosis is involved in the pathogenesis of emphysema, a prevalent disease primarily caused by cigarette smoking. We report that ceramide, a second messenger lipid, is a crucial mediator of alveolar destruction in emphysema. Inhibition of enzymes controlling de novo ceramide synthesis prevented alveolar cell apoptosis, oxidative stress and emphysema caused by blockade of the vascular endothelial growth factor (VEGF) receptors in both rats and mice. Emphysema was reproduced with intratracheal instillation of ceramide in naive mice. Excessive ceramide triggers a feed-forward mechanism mediated by activation of secretory acid sphingomyelinase, as suggested by experiments with neutralizing ceramide antibody in mice and with acid sphingomyelinase-deficient fibroblasts. Concomitant augmentation of signaling initiated by a prosurvival metabolite, sphingosine-1-phosphate, prevented lung apoptosis, implying that a balance between ceramide and sphingosine-1-phosphate is required for maintenance of alveolar septal integrity. Finally, increased lung ceramides in individuals with smoking-induced emphysema suggests that ceramide upregulation may be a crucial pathogenic element and a promising target in this disease that currently lacks effective therapies.
Pulmonary emphysema, which along with chronic bronchitis comprises the chronic obstructive pulmonary diseases, is a highly prevalent lung disease, with no effective treatments. Emphysema involves a destructive and permanent enlargement of distal airspaces and alveolar walls 1 , ultimately leading to impaired oxygenation. Historically, the pathogenesis of emphysema has been linked to chronic lung inflammation causing protease-antiprotease imbalance 2 .
It has recently been recognized that alveolar cell apoptosis is a crucial step in emphysema [3] [4] [5] [6] , accounting for the unique nature of alveolar septal destruction when compared with other lung diseases also characterized by inflammation and increased matrix proteolysis. The mutual interactions among apoptosis, inflammation, oxidative stress and matrix proteolysis might account for the irrevocable progression of the disease despite smoking cessation 4 . Because ceramide is a prototypic second messenger molecule that modulates endothelial cell apoptosis 7 , oxidative stress 7 and proteolysis 8 , we hypothesize that ceramide upregulation induces alveolar cell apoptosis and oxidative stress, amplifying lung destruction and thus causing emphysema.
The signaling mediated by ceramide has been suggested to be involved in fundamental eukaryotic cell functions, such as cellular differentiation, stress response, apoptosis and senescence 7, 9 . Studies have shown a direct role for ceramide in the development of several neurological diseases as well as radiation-induced injury 10, 11 , which share with emphysema a central function for apoptosis and oxidative stress in their pathogenesis.
The proapoptotic effects of ceramide are mediated by a variety of mechanisms (e.g., activation of kinase suppressor of Ras 12 , protein phosphatases 1 and 2A 13 , cathepsin D 14 , or through direct alteration of plasma 15 or mitochondrial 16 membrane signaling properties). Enzymatically, ceramide is synthesized primarily through a de novo pathway involving serine palmitoyl-CoA transferase and ceramide synthase or from membrane sphingomyelin breakdown by sphingomyelinases ( Supplementary Fig. 1 online) . The acid sphingomyelinase (ASMase), recently thought to be involved in the development of acute lung edema 17 , has lysosomal and secretory isoforms, the latter contributing to extracellular increases in ceramide 10 . A downstream product of ceramide metabolism is sphingosine-1-phosphate (S1-P) which, contrary to ceramide, mediates cell survival and proliferation 18 . Current evidence indicates that a balance between ceramide and S1-P levels regulates cellular survival and homeostasis 19, 20 .
Given that ceramide may be an upstream signaling mediator of apoptosis and oxidative stress, to investigate the role of ceramide in alveolar wall destruction, we used the apoptosis-and oxidative stress-dependent emphysema model caused by inhibition of VEGF receptors (VEGFR) in rats 3 and mice. The advantage of this approach is that both the VEGFR blockade model and human emphysema share the crucial pathobiological elements of apoptosis, oxidative stress, decreases in alveolar capillaries and alveolar destruction 2, 21 . We then translated our findings to the human disease by analyzing ceramide expression in lungs of individuals with cigarette smoke-induced emphysema.
RESULTS
Ceramide upregulation in VEGFR blockade-induced emphysema SU5416, a specific inhibitor of VEGFR-1 and VEGFR-2, induces apoptosis-and oxidative stress-dependent alveolar septal destruction and emphysema in rats 3, 5 and mice 21 d after its administration. VEGFR blockade promptly increased lung ceramide levels, approximately twofold at 3 d in the mouse lung (Fig. 1a) and threefold at 1 d in the rat lung (Fig. 1b) , compared to vehicle. The enhanced ceramide expression in response to VEGFR inhibition was localized to the alveolar septal cells, whereas expression in bronchial epithelium was similar to that of controls (Fig. 1a) . Ceramide increased concurrently with enhanced expression of markers of oxidative stress and apoptosis, such as 8-hydroxy-guanosine and active caspase-3, respectively, which peaked at 3 d 5 ( Supplementary Fig. 2 online) , thus preceding the airspace enlargement (which typically peaks at 21-30 d in this model).
We then measured the activity of enzymes crucial for SU5416-induced lung ceramide synthesis and levels of specific ceramide metabolites at the time of ceramide upregulation. VEGFR blockade activated ceramide synthase rapidly, up to threefold at 3 d (Fig. 1c) . The earliest changes in the sphingomyelinase pathway were noted after 3 d, with modest activation of only the secretory (soluble) ASMase, whereas activities of both the lysosomal ASMase and the neutral sphingomyelinase did not increase above baseline (Fig. 1d,e) . VEGFR blockade increased the levels of direct precursors of ceramide in the de novo pathway (Supplementary Fig. 1 online) , dihydro-sphingosine (measured as dihydro-sphingosine-P) and dihydroceramide, at the time of ceramide elevation, whereas S1-P levels remained unchanged versus controls (Fig. 1f) . In aggregate, these results indicate the de novo pathway as the major mechanism of early ceramide synthesis in response to VEGFR blockade.
Inhibition of de novo ceramide synthesis blocks emphysema
We inhibited the early (up to 5 d) de novo ceramide production with fumonisin B1 (FB1) and myriocin, specific inhibitors of ceramide synthase and serine palmitoyl transferase, respectively. FB1 attenuated SU5416-induced alveolar septal destruction in both mice and rats (Fig. 2a) . The VEGFR blockade-induced increase in alveolar diameter was inhibited in a dose-dependent manner by FB1 pretreatment (Table 1) in mice and most markedly in rats (Fig. 2a,b and Table 1 ). The inhibitory effect was accounted for primarily by a decrease in the number of severely damaged distal airspaces ( Supplementary Fig. 3 online) . FB1 decreased lung ceramide induced by the VEGFR blockade by 57% (P = 0.04) at 3 d and by 32% (P = 0.05) at 7 d in mouse and rat, respectively (data not shown) and markedly decreased both oxidative stress and apoptosis induced by VEGFR blockade (Fig. 2c,d) .
Notably, control animals treated with high-dose FB1 alone showed increased alveolar size (Fig. 2a,b and Table 1 ), an effect potentially explained by excessive apoptosis as reported in the kidneys and liver 22 . Consistent with the hypothesis that FB1 induced cellular apoptosis by inhibiting downstream prosurvival sphingolipids, S1-P supplementation (by concomitant administration of the S1-P analog FTY720 (refs. 23,24) ) abolished both FB1-induced apoptosis and airspace enlargement ( Supplementary Fig. 3 online) . To address the potential lack of specificity inherent to pharmacological inhibitors such as FB1, we inhibited the upstream enzyme in the de novo pathway, serine palmitoyl trans- ferase, with myriocin. Similar to FB1, early ceramide synthesis inhibition with myriocin attenuated SU5416-induced morphometric changes ( Table 1 ) and decreased the number of severely damaged airspaces in mice ( Supplementary Fig. 3 online), supporting our hypothesis that synthesis of abnormally high levels of ceramide causes lung cell apoptosis, oxidative stress and subsequent emphysema in VEGFR-inhibited animals.
We previously reported that caspase-dependent apoptosis was required for airspace enlargement in rats treated with a VEGFR blocker 3 and that oxidative stress and apoptosis form a mutually interactive feedback loop in this emphysema model 5 . To clarify the cause-effect relationship between ceramide signaling and alveolar cell apoptosis, we measured ceramide levels in morphometrically normal rat lung resulting from coadministration of the VEGFR inhibitor with a caspase inhibitor (z-Asp-CH (2) -DCB), as compared to emphysematous lungs caused by VEGFR inhibition alone. We detected similar elevations in ceramide in both conditions, suggesting that ceramide increases upstream of caspase activation ( Supplementary Fig. 3 online) .
Finally, to confirm the causal role of ceramide in emphysema development in this model, we counteracted the biological effects of ceramide by augmenting S1-P-engaged signaling at the time of VEGFR blockade-induced lung ceramide. Administration of the SP-1 analog markedly inhibited lung cell apoptosis induced by VEGFR inhibition, implicating a requirement for ceramide-S1-P balance in the maintenance of alveolar cell survival (Fig. 2e) .
Augmentation of lung ceramide levels causes acute emphysema
Given that acute increases in ceramide cause apoptosis 25 , we tested whether direct intratracheal instillation of ceramide recapitulates the phenotype of the VEGFR blockade, namely alveolar septal cell apoptosis, oxidative stress and emphysema. Because naturally occurring long-and very long-chain ceramides have important experimental limitations resulting from poor cell permeability, we utilized synthetic short-chain ceramide for exogenous administration. Low-dose (1 mg/kg mixed in perfluorocarbon) or high-dose (10 mg/kg) C 12 ceramide was instilled intratracheally into mouse lung.
C 12 ceramide instillation increased total lung ceramide levels in a dose-dependent manner when normalized by tissue weight (Fig. 3a) , or tissue lipid (twofold increase in the lowdose C 12 group (14.5 pmol/nmol lipid P i ) and 4.8-fold increase in the high-dose group versus control (7 pmol/nmol)). The increased lung ceramide levels were equivalent to those induced by VEGFR blockade. Notably, a single lung instillation of C 12 caused dose-dependent increases in alveolar diameters at 1 d (Fig. 3b) , which persisted through 6 d (a 7% increase; P = 0.01, data not shown). Clearly, the alveolar enlargement was ceramide specific, as dihydroceramide (1 mg/kg, intratracheal), the biologically inactive ceramide precursor, did not alter alveolar diameters (Fig. 3b) . Notably, neither C 12 ceramide nor its negative control dihydroceramide caused alveolar collapse or extensive neutrophilic infiltrate in the time frame studied. C 12 ceramide instillation acutely triggered apoptosis, as measured by marked active caspase-3 expression (Fig. 3c) , in situ TUNEL, and elevated Bax levels in the lung ( Supplementary Fig. 4 online). Costaining with cell-specific markers showed that type II alveolar epithelial cells and mostly endothelial cells underwent apoptosis triggered by ceramide instillation (Fig. 3d) . The ceramide-induced airspace enlargement was dependent on caspase activation, as it was prevented by pretreatment with a general caspase inhibitor (Fig. 3e) . Ceramide-induced alveolar cell apoptosis and septal destruction were associated with enhanced oxidative stress (8-hydroxy-guanosine, Supplementary Fig. 3 online) . Acute increases in ceramide also activated lung matrix proteolysis, detected by activation of MMP-12 (macrophage metalloelastase; Fig. 3f ), a protease thought to be involved in smokinginduced emphysema 26 , and by zymography (Fig. 3g) . The ceramideinduced MMP-12 activation was accompanied by increased numbers of resident lung macrophages, the main source of MMP-12 (Fig. 3h) .
Positive feedback of ceramide synthesis in emphysema
The functional effects of exogenously administered short-chain ceramides are explained by either intracellular fatty acid chain elongation, or by endogenous ceramide synthesis stimulation 27 . The importance of the latter mechanism is in the initiation of a positive feedback of ceramide synthesis, allowing for amplification of apoptosis and lung destruction.
We sought to probe the presence of such a mechanism by first measuring ceramide species by liquid chromatography-tandem mass spectroscopy (LC-MS/MS) in the mouse lung at baseline and 24 h after C 12 ceramide instillation (Fig. 4a) . Although no changes were detected in levels of unsaturated ceramides, C 12 ceramide increased by 20% the endogenous saturated very long-chain ceramide (C 24 ) and decreased levels of long-chain ceramides (C 16 , C 18 ). These findings were partly confirmed with cultured lung endothelial cells treated with short-chain ceramide (C 8 , 10 µM, which causes lung endothelial cell apoptosis, data not shown). C 8 ceramide markedly increased the levels of endogenous very long-chain (C 20 -C 26 ) and long-chain (C 14 -C 18 ) ceramides in cultured pulmonary endothelial cells (Fig. 4b) .
The shift toward synthesis of very long-chain ceramide after C 12 ceramide instillation was associated with significant activation of lung ASMase activity (1.5-fold, P = 0.02; Fig. 4c ), suggesting sphingomyelin breakdown as a source of amplified endogenous ceramide production.
The sequential activation of the secretory, but not lysosomal ASMase after the activation of ceramide synthase by VEGFR blockade (Fig. 1d) could result from a feed-forward mechanism of ceramide synthesis, thus increasing the pool of ceramide in the immediate extracellular space (paracellular) and amplifying lung injury. To investigate the role of extracellular ceramide released in response to VEGFR blockade, we administered systemically a ceramide-specific antibody during VEGFR inhibition in mice. The neutralizing ceramide antibody decreased by 30% lung very long-chain ceramides (Fig. 4d) and attenuated lung apoptosis induced by the VEGFR inhibitor at 3 d, as detected by immunohistochemistry (IHC; Fig. 4e ) and caspase-3 activity assay (∼20% decrease), but did not inhibit the matrix proteolytic activity induced by SU5416 (data not shown). These effects were less potent than those resulting from the inhibition of de novo ceramide synthesis. They suggested, however, the presence of an active paracellular ceramide pool, potentially generated from plasma membrane sphingomyelin through a ceramide-triggered positive feedback mechanism.
We investigated in more detail this amplification mechanism using ASMase-deficient human fibroblasts derived from individuals with Niemann-Pick disease. In response to ceramide (C 8 ), but not dihydroceramide, ASMase-deficient fibroblasts did not increase the amount of endogenous ceramides secreted in the media as compared to wild-type cells ( Supplementary Fig. 5 online) . These changes affected the most abundant ceramide species: C 16:0 , C 24:1 and C 24:0 (which together constitute >90% of secreted ceramide), but not C 14:0 (∼1%). The ASMasedeficient cells showed an early resistance to exogenous ceramide-induced apoptosis (at 4 h). These differences persisted albeit as a trend at 8 h and 24 h (Supplementary Fig. 5 online) . The apoptosis induced by exogenous ceramide in ASMase-deficient cells was de novo synthesis-dependent, as it was blocked by myriocin, whereas wild-type cell apoptosis probably involved myriocin-independent pathways (i.e., ASMase; Supplementary Fig. 5 online) . These data suggest that ASMase amplifies ceramide synthesis in a paracellular manner and that exogenous ceramide-induced apoptosis requires both de novo and ASMasemediated endogenous ceramide generation.
Increased lung ceramides in patients with emphysema
To translate our results to human emphysema (primarily caused by cigarette smoking), ceramide levels were measured in lung endothelial cells exposed to cigarette smoke. In bovine endothelial cells, which compared to cultured human endothelial cells are more sensitive to apoptotic stimuli 28 , cigarette smoke induced rapid, sustained ceramide upregulation, partially inhibited by FB1 (Fig. 5a) . Cigarette smoke induced ceramide to a similar extent as tumor necrosis factor (TNF)-α (Fig. 5a) , a proinflammatory cytokine involved in emphysema 29 and a classical stimulus of ceramide synthesis in endothelial cells 30 .
We next analyzed ceramide expression levels and localization in lung samples from human emphysema (clinical characteristics in Supplementary Table 1 online). Lung ceramide levels were markedly higher in individuals with emphysema from chronic cigarette smoking compared to individuals without emphysema, as measured by IHC, diacylglycerol (DAG) kinase assay (Fig. 5b,c) and high-performance liquid chromatography (HPLC; data not shown). In individuals with emphysema, the increases in ceramide were almost exclusively localized to alveolar septal cells and alveolar macrophages (Fig. 5b) , whereas the expression of ceramide in large airways and vessels was not different from that of controls (data not shown). Further analysis showed that compared to nonemphysema lungs, human emphysematous lungs show a significant increase in long-chain ceramides (P < 0.05; Fig. 5d,e) . Even smoking alone (without a pathological diagnosis of emphysema) changed the lung ceramide expression profile (Fig. 5d) , suggesting that not only absolute levels, but also patterns of ceramide species expression may be important in emphysema.
DISCUSSION
Our data suggest that increases in lung ceramide are required and amplify alveolar cell apoptosis, oxidative stress and emphysema caused by VEGFR blockade. Furthermore, we determined that increases in ceramide sufficed to cause emphysema in an animal model and that ceramide functioned proximally to apoptosis. The LC-MS/MS profiles of ceramide species in the lungs from mice, rats and humans indicated that both an increase in absolute levels and a change in the profiles of ceramide species were important in emphysema development.
Although the precise functional significance of the latter phenomenon remains unclear 31 , our findings indicated that an absolute upregulation of ceramide was involved in the disappearance of alveolar septae in emphysema. Endothelial cells are particularly susceptible to ceramidedependent apoptosis 32 and their excessive apoptosis contributes to emphysema pathogenesis 3, 6, 33 . As molecular targets of ceramide mediate not only apoptosis, but also matrix proteolysis (through MMPs or cathepsin D 14 ), the effects of ceramide would extend beyond endothelial apoptosis. Similarly, upregulated ceramide may be a new link between pathological apoptosis and monocyte inflammation (e.g., through CD14 clustering 34 ) in the lung. As seen in our model of ceramide-induced emphysema, ceramide-stimulated macrophages could generate further lung proteolysis and damage. Therefore inflammation, rather than preceding, might follow excessive apoptosis and, as recently shown in the Nrf-2 knockout mouse 6 , oxidative stress, which together overwhelm cellular maintenance and antioxidant defense mechanisms, respectively. Our results firmly position ceramide upstream in the apoptosis cascade and oxidative stress induced by VEGFR blockade. The hierarchical cause-effect relationship among inflammation, oxidative stress and apoptosis is crucial for the development of susceptibility markers and targets of therapy.
The main mechanism of rapid ceramide upregulation in our model was through the de novo pathway. It is conceivable that VEGFR inhibition stimulates de novo ceramide synthesis as part of the stress response 35 triggered by deprivation of lung endothelial cell survival factors 36 or by oxidative stress 37, 38 . We also provide evidence of (delayed) stimulation of the secretory ASMase, directly by the VEGFR inhibitor, or indirectly by the initial ceramide burst. This second wave of ceramide release may contribute to increased ceramide at the exoplasmic plasma membrane, sustaining a feed-forward ceramide production. Using ceramide-neutralizing antibodies, we confirmed the contribution of paracellular ceramide to alveolar cell apoptosis in our model. This ceramide could have originated from dying cells or through secretory ASMase activation. The direct proof of the role of sphingomyelinase vis-à-vis the de novo pathway in the ceramide amplification requires the use of transgenic animals, of which only the ASMase knockout is available 39, 40 . It should be noted that deletion of the gene that encodes ASMase alters cellular and organ structure primarily by excessive accumulation of sphingomyelin. In this mouse model of Niemann-Pick disease, the lung shows increased inflammation resulting from an alveolar macrophage defect in surfactant clearance 41 , thus showing a complex phenotype with unclear relevance to human emphysema. We expanded and confirmed the in vivo data using human ASMase-deficient fibroblasts from individuals with NiemannPick disease. Notably, because endothelial cells have the most abundant levels of secretory ASMase 10 , injured lung capillary endothelial cells may exacerbate cellular damage in emphysema by this amplification mechanism, a potential explanation for the sustained lung damage present despite discontinuation of smoking 42 .
Specific blockers of the de novo pathway inhibited emphysema in our model. Nevertheless, excessive ceramide synthase inhibition with FB1 alone triggered emphysema-like changes in both mice and rats. These effects may reflect a biological variation, or toxicity mediated by depletion of cellular pools of sphingolipids. This apparent limitation of the use of FB1 led us to show that S1-P supplementation not only prevented FB1-induced apoptosis, but also inhibited VEGFR blockade-induced Table 1 online) by (b) immunostaining showed that in individuals without emphysema (Ctl) ceramide was expressed mostly by alveolar macrophages (arrow), whereas in emphysema (Emph), ceramide was increased in alveolar septal endothelial and epithelial II and I (arrowhead) cells and macrophages; (*P = 0.02); by (c) DAG kinase assay (means ± s.d.; *P = 0.01); and by (d,e) LC-MS/MS (emphysema, black; nonemphysema nonsmokers, light gray; nonemphysema smoker (Smk), gray). *P < 0.05. apoptosis. Our results might be interpreted that a tonic prosurvival effect engaged by the ceramide-S1-P pathway, shown in ovary 43 , is also required for alveolar septal homeostasis.
Can we translate these findings to human disease? In our study of human emphysema, we consistently measured increased ceramide, with intense alveolar septal localization, recapitulating the findings of the VEGFR blockade model. We performed most ceramide measurements in individuals with progressive deterioration in lung function despite quitting smoking at least 1 year before specimen collection. These late ceramide increases may be the result of ongoing oxidative stress, VEGF depletion, inflammation and apoptosis, all consequences of previous smoking, all creating a spiraling amplification of lung destruction.
In conclusion, we established that de novo ceramide synthesis is required for the development of murine lung emphysema and that ceramide expression is markedly increased in lungs of individuals with cigarette smoke-induced emphysema. Confirming ceramide as a link between excessive apoptosis and inflammation, and extending our studies in human emphysema may uncover new markers for genetic predisposition and disease severity and offer new targets to slow the alveolar destruction in this prevalent lung disease.
METHODS
Animal studies. Animal studies were approved by the Johns Hopkins Animal Care and Use Committee. The rat model of emphysema has been previously described 3 . We subcutaneously administered 20 mg/kg SU5416 (SUGEN, Inc.) once to either male Sprague-Dawley rats (3 months old, 300 g, Harlan) or male C57BL/6 mice (3 months old, 25 g, Jackson Laboratory). Experiments were performed in the same shipment lot (n = 4-6 rats or mice per group). FB1 (2.2 mg/kg or 1.1 mg/kg in 1 ml (rat) or 300 µl (mouse)) in phosphate-buffered saline was administered intraperitoneally for 5 d. We similarly gave myriocin to mice at doses of 1 mg/kg or 0.3 mg/kg. Neutralizing ceramide antibodies (4 mg/kg) or isotype antibodies were dialyzed and then administered intraperitoneally to mice daily for 3 d after the administration of the VEGFR inhibitor. The lungs of rats given Z-Asp-CH (2) -DCB were from the experiment previously reported 3 . The S1-P analog, FTY720, provided by J. Garcia and S. Dudek (The Johns Hopkins University), or vehicle (0.1% DMSO in saline) was given intraperitoneally (0.1 mg/kg) 23 for 5 d either concomitant with FB1, or after the injection of SU5416. For intratracheal instillation, we solubilized ceramide or dihydroceramide in ethanol and delivered it at the base of the protruded tongue in 80-100 µl perfluorocarbon (1:5 vol/vol). For negative control, we delivered similarly prepared dihydroceramide 1 mg/kg. Z-Asp-CH (2) -DCB (Alexis) was given (3 mg/kg intraperitoneally or vehicle 0.1% DMSO in saline) 1 h before ceramide instillation. In this set of experiments, ceramide and its control were given by direct intratracheal injection (30 µl vehicle 1% ethanol, 1% bovine serum albumin in saline).
Cell culture experiments. We stimulated cells with cigarette smoke extract (0.5-1% vol/vol) in the culture media 44 Ceramide determination. We used complementary methods to measure and to qualify the species of lung tissue ceramide: diacylglycerol (DAG) kinase assay, HPLC and mass spectroscopy, which relied on the concomitant use of ceramide standards, followed by normalization per tissue weight, protein or lipid concentration. Additionally, ceramide was detected by IHC. Tissue or cellular lipids were extracted 45 and lipid content was assessed by measurements of total lipid phosphorus (P i ) 46 . DAG kinase assay 47 and HPLC 48 are detailed in Supplementary Methods online. We used a modification of the LC-MS/MS 49 for detecting sphingosine and dihydrosphingosine, seven major ceramide molecular species and three major dihydroceramide species. S1-P was analyzed as diacetate derivative to reduce S1-P carryover 50 . We performed detection of ceramide by IHC in paraffin-embedded sections with a ceramide-specific antibody (1:60, 1 h for mouse tissue and 1:100, 1 h for human and rat tissue) with Dako Animal Research Kit (Dako). We used isotype antibody, as well as adsorbed antibody, as controls by preincubating the ceramide antibody with a saturating C 8 ceramide solution. Quantification of ceramide expression is presented in Supplementary Methods online. The acid and neutral sphingomyelinase and ceramide synthase activities were measured as described 46 and with the Amplex E Red Sphingomyelinase Assay Kit (Molecular Probes).
Morphometric analysis.
We performed morphometric analysis on coded slides as described 5 .
Apoptosis. Active caspase-3 IHC was performed using a Catalyzed Signal Amplification kit (Dako) 5 . Measurements of active caspase-3 were performed on 10-15 images per slide captured by independent observers blinded to the experiment 5 . The caspase-3 activity was measured by colorimetric (Clontech Laboratories) and fluorometric (Apo-ONE, Promega) assays. We performed TUNEL using a terminal deoxyribonucleotide transferase apoptosis detection kit (Oncogene). For colocalization studies, we performed TUNEL in parallel with fluorescent IHC for CD34 and SPC, markers for endothelial and type II epithelial cells, respectively. Nucleosomal ELISA kit was from Calbiochem.
Oxidative stress measurements. Detection of 8-hydoxy-guanosine was performed by IHC on paraffin-embedded sections 5 .
Lung matrix proteolytic activity. We analyzed lung matrix proteolytic activity of nondenatured protein extracts from lung tissues by gelatin and casein zymogram gels (Novex). MMP-12 levels were analyzed by western blotting. We detected lung macrophages by Mac 3 IHC.
Statistical analysis.
Mean values between two groups were compared using Student t-test. Morphometry results were analyzed by Kruskal-Wallis One Way Analysis of Variance on Ranks (SigmaStat, SPSS Inc).
Note: Supplementary information is available on the Nature Medicine website.
